A comparative study of atorvastatin and rosuvastatin in dyslipidemia


  • Rudip Thapa Department of Clinical Pharmacology, Nepal Medical College, Atterkhel, Kathmandu, Nepal
  • Prakash Rai Department of Clinical Pharmacology, Nepal Medical College, Atterkhel, Kathmandu, Nepal
  • Laxmi Mahara International Friendship Children's Hospital, Maharajgunj, Kathmandu, Nepal
  • Sudarsana Chetty Department of Pharmacology, College of Medical Science, Bharatpur, Nepal




Atorvastatin, Dyslipidemia, Rosuvastatin


Background: To compare the drugs: Atorvastatin (10mg) and Rosuvastatin (5mg) in patients with Dyslipidemia.

Methods: This open-label, randomized, parallel group, comparative, prospective study of six months duration included 100 patients. The age group of patients varied from 30 to 69 years with dyslipidemia. Patients were divided in to 2 groups. 50 patients in group-1 received Atorvastatin 10mg once daily and 50 patients in group-2 received Rosuvastatin 5 mg once daily. The level of TC, TG, LDL, VLDL and HDL were assessed at baseline and at the end of 3 months and 6 months.

Results: At 3 months, LDL was reduced significantly more with 5mg Rosuvastatin than with Atorvastatin 10 mg [43.68% vs. 40.74% (P 0.0049)]. At 6 months, Rosuvastatin 5mg reduced LDL significantly more than Atorvastatin 10 mg [48.69% vs. 43.85% (P 0.00)]. TC, HDL, TG and VLDL were more favourably modified by Rosuvastatin at 6 months (P <0.005). Reduction of total cholesterol levels in Rosuvastatin group was not statistically significant when compared with Atorvastatin group (P 0.103).

Conclusions: Rosuvastatin 5mg was more efficacious than Atorvastatin 10mg for the improvement of lipid profile during the period of 6 months follow-up drug therapy in patients with dyslipidemia.


Zhang XH, Lu ZL, Liu L. Coronary heart disease in China. Heart. 2008;94(9):1126-31.

Rang HP, Dale MM, Ritter JM, Flower RJ. Rang & Dale’s Pharmacology, 6th Ed. Elsvier, Churchill Livingstone, Philadelphia; 2007.

Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89-92.

Lloyd-Jones DM, Leip EP, Larson MG, D’Agostino RB, Beiser A, Wilson PWF, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791-8.

Grundy SM, D'Agostino S, Mosca L, Burke GL, Wilson PWF, Rader DJ, et al. Cardiovascular risk assessment based on U.S. cohort studies: findings from a national heart, lung, and blood institute workshop. Circulation. 2001;104:491.

Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867-2.

Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol. 2002;22:1524-34.

Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001;357:1063-8.

Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504.

Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:1814-21.

Robert KM, Daryl KG, Peter AM, Victor WR. Harper’s Illustrated Biochemistry: Lipid Transport & Storage. 26th Ed. The McGraw-Hill Companies; 2003.

Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.

Kuryata OV, Yegorova YV. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis. Kardiol Pol. 2006;64(1):44-8.

Gao RL. The efficacy and safety of rosuvastatin on treating patients with hypercholesterolemia in Chinese: a randomized, double-blind, multi-center clinical trial. Zhonghua xin xue guan bing za zhi. 2007 Mar;35(3):207-11.

Save V, Patil N, Moulik N, Rajadhyaksha G. Effect of atorvastatin on type 2 diabetic dyslipidemia. J Cardiovasc Pharmacol Ther. 2006;11(4):262-70.

Teramoto T, Watkins C. Review of efficacy of rosuvastatin 5mg. Int J Clin Pract. 2005;59(1):92-101.

Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J. 2004;148(1):4.

Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol. 2003;91(5A):3-10.

Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of Rosuvastatin and Atorvastatin across their dose range in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 2003;91:33-41.

Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, Hutchinson H. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002;89(3):268-75.

Kurabayashi M, Yamazaki T. Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins. J Atheroscler Thromb. 2008;15(6):314-23.

Park JS, Kim YJ, Choi JY, Kim YN, Hong TJ, Kim DS, et al. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. Korean J Intern Med. 2010;25(1):27-35.

Mazza F, Stefanutti C, Di Giacomo S, Vivenzio A, Fraone N, Mazzarella B, et al. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia. Am J Cardiovasc Drugs. 2008;8(4):265-70.

Otokozawa S, Ai M, Asztalos BF, Nakajima K, Stein E, Jones PH, et al. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol. 2008;101(3):315-8.

Lloret R, Ycas J, Stein M, Haffner S. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). Am J Cardiol. 2006;98(6):768-73.

Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 2002;144(6):1044-51.




How to Cite

Thapa, R., Rai, P., Mahara, L., & Chetty, S. (2017). A comparative study of atorvastatin and rosuvastatin in dyslipidemia. International Journal of Basic & Clinical Pharmacology, 6(11), 2551–2555. https://doi.org/10.18203/2319-2003.ijbcp20174769



Original Research Articles